CAPITROL Drug Patent Profile

Which patents cover Capitrol, and when can generic versions of Capitrol launch?

Capitrol is a drug marketed by Westwood Squibb and is included in one NDA.

The generic ingredient in CAPITROL is chloroxine. Additional details are available on the chloroxine profile page.

Summary for CAPITROL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CAPITROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Westwood Squibb	CAPITROL	chloroxine	SHAMPOO;TOPICAL	017594-001	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for CAPITROL

See the table below for patents covering CAPITROL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	297940
Belgium	710394
Switzerland	495749	Mittel zur Beseitigung von Schuppen auf der Kopfhaut
Germany	1617836	HAARBEHANDLUNGSMITTEL ZUR BESEITIGUNG VON SCHUPPEN AUF DER KOPFHAUT
Denmark	124586

CAPITROL patent, exclusivity, and investment fundamentals analysis (IP risk, FDA status, and generic/biosimilar threat)

Last updated: July 26, 2026

CAPITROL is not identifiable as a specific, FDA-defined pharmaceutical product or active ingredient based on the provided prompt alone. Without a uniquely verifiable drug identity (active ingredient, dosage form, NDA/BLA/RLD, manufacturer), it is not possible to produce an accurate investment scenario grounded in patent estates, Orange Book status, exclusivity timelines, or litigation risk.

What is CAPITROL (active ingredient) and what FDA product is it?
No response.

What patents protect CAPITROL and how strong is the patent estate?
No response.

When does CAPITROL lose exclusivity (market exclusivity, patent term, and regulatory exclusivities)?
No response.

What is the Orange Book status of CAPITROL (NDA listings, patents, exclusivity codes)?
No response.

Are there Paragraph IV challenges for CAPITROL, and which companies are filing?
No response.

What patent litigation affects CAPITROL (as-filed, settlements, consent judgments, stays)?
No response.

What formulations are protected by CAPITROL patents (IR/ER, salts, particle engineering, combination products)?
No response.

What method-of-use patents cover CAPITROL (indications, dosing regimens, patient subsets)?
No response.

How does CAPITROL compare with competing drugs (same MOA, same class, and alternative delivery systems)?
No response.

What generic entry risks exist for CAPITROL (launch timing, manufacturing/IP barriers)?
No response.

Key takeaways
No response.

FAQs

1. No response.
2. No response.
3. No response.
4. No response.
5. No response.

References

No response.